Truist Securities Reiterates Buy on Revolution Medicines, Raises Price Target to $261

Benzinga · 3d ago
Truist Securities analyst Gregory Renza reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $241 to $261.